UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 164

Sortiert nach

High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy

Neurology, 2019-01, Vol.92 (1), p.e48

2019

Volltextzugriff (PDF)

Botulinum Neurotoxin Is Shielded by NTNHA in an Interlocked Complex

Science (American Association for the Advancement of Science), 2012-02, Vol.335 (6071), p.977-981

2012

Volltextzugriff (PDF)

The role of human serum albumin and neurotoxin associated proteins in the formulation of BoNT/A products

Toxicon (Oxford), 2019-10, Vol.168, p.158-163

2019

Volltextzugriff (PDF)

Botulinum Neurotoxins: Qualitative and Quantitative Analysis Using the Mouse Phrenic Nerve Hemidiaphragm Assay (MPN)

Toxins, 2015-11, Vol.7 (12), p.4895-4905

2015

Volltextzugriff (PDF)

The HCC‐domain of botulinum neurotoxins A and B exhibits a singular ganglioside binding site displaying serotype specific carbohydrate interaction

Molecular microbiology, 2004-02, Vol.51 (3), p.631-643

2004

Volltextzugriff (PDF)

Heinrich Heesch: Kristallgeometrie, Parkettierungen, Vierfarbenforschung

Bigalke, Hans G

1, 1988

Volltextzugriff (PDF)

Clinical relevance of neutralizing antibodies in botulinum toxin long-term treated still-responding patients with cervical dystonia

Therapeutic advances in neurological disorders, 2019, Vol.12, p.1756286419892078-1756286419892078

2019

Volltextzugriff (PDF)

Synaptotagmins I and II Act as Nerve Cell Receptors for Botulinum Neurotoxin G

The Journal of biological chemistry, 2004-07, Vol.279 (29), p.30865-30870

2004

Volltextzugriff (PDF)

Botulinum toxin type D blocks autonomic cholinergic synapses in humans: discussion of a potential therapeutic use

Journal of Neural Transmission, 2019-10, Vol.126 (10), p.1337-1340

2019

Volltextzugriff (PDF)

Identification of the protein receptor binding site of botulinum neurotoxins B and G proves the double-receptor concept

Proceedings of the National Academy of Sciences - PNAS, 2007-01, Vol.104 (1), p.359-364

2007

Volltextzugriff (PDF)

The biological activity of botulinum neurotoxin type C is dependent upon novel types of ganglioside binding sites

Molecular microbiology, 2011-07, Vol.81 (1), p.143-156

2011

Volltextzugriff (PDF)

Botulinum neurotoxin serotype D attacks neurons via two carbohydrate-binding sites in a ganglioside-dependent manner

Biochemical journal, 2010-10, Vol.431 (2), p.207-216

2010

Volltextzugriff (PDF)

Two Carbohydrate Binding Sites in the HCC-domain of Tetanus Neurotoxin are Required for Toxicity

Journal of molecular biology, 2003-02, Vol.326 (3), p.835-847

2003

Volltextzugriff (PDF)

SNARE tagging allows stepwise assembly of a multimodular medicinal toxin

Proceedings of the National Academy of Sciences - PNAS, 2010-10, Vol.107 (42), p.18197-18201

2010

Volltextzugriff (PDF)

Botulinum neurotoxin type A in urology: Antibodies as a cause of therapy failure

International journal of urology, 2008-05, Vol.15 (5), p.407-415

2008

Volltextzugriff (PDF)

Long-term stability of reconstituted incobotulinumtoxinA: how can we reduce costs of botulinum toxin therapy?

Journal of Neural Transmission, 2017-10, Vol.124 (10), p.1223-1225

2017

Volltextzugriff (PDF)

Reconstituting botulinum toxin drugs: shaking, stirring or what?

Journal of Neural Transmission, 2016-05, Vol.123 (5), p.523-525

2016

Volltextzugriff (PDF)

Reconstituting botulinum toxin drugs: Shaking, stirring or what?

Toxicon (Oxford), 2016-12, Vol.123, p.S23-S23

2016

Volltextzugriff (PDF)

Comparing incobotulinumtoxina (Xeomin) and onabotulinumtoxina (Botox): Identical potency labeling in the hemidiaphragm assay

Toxicon (Oxford), 2016-12, Vol.123, p.S23-S23

2016

Volltextzugriff (PDF)

Complexing proteins: Are they necessary for mechanical stability of botulinum toxin drugs?

Toxicon (Oxford), 2016-12, Vol.123, p.S23-S23

2016

Volltextzugriff (PDF)

The immunology of botulinum toxin therapy: A brief summary

Toxicology (Amsterdam), 2022-11, Vol.481, p.153341, Article 153341

2022

Volltextzugriff (PDF)

Botulinum toxin: application, safety, and limitations

Current topics in microbiology and immunology, 2013, Vol.364, p.307

Bigalke, Hans

2013

Volltextzugriff (PDF)

Comparing incobotulinumtoxinA (Xeomin®) and onabotulinumtoxinA (Botox®): identical potency labelling in the hemidiaphragm assay

Journal of Neural Transmission, 2018-09, Vol.125 (9), p.1351-1354

2018

Volltextzugriff (PDF)

Botulinum toxin A and the cutaneous nociception in humans: A prospective, double-blind, placebo-controlled, randomized study

Journal of the neurological sciences, 2002-12, Vol.205 (1), p.59-63

2002

Volltextzugriff (PDF)

Botulinum toxin antibody type A titres after cessation of botulinum toxin therapy

Movement disorders, 2002-01, Vol.17 (1), p.170-173

2002

Volltextzugriff (PDF)

1 – 25 von 164

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(127)
Mit Volltextzugriff
(145)

Publikationsform

Sprache

Englisch
(133)
Deutsch
(32)
Japanisch
(17)

Erscheinungsjahr

n.n

Thema

Science & Technology
(83)
Life Sciences & Biomedicine
(81)
Humans
(48)
Animals
(45)
Neurosciences & Neurology
(43)
Biological And Medical Sciences
(35)
Mice
(34)
Clinical Neurology
(32)
Male
(32)
Neurosciences
(31)
Female
(30)
Medical Sciences
(25)
Neurology
(24)
Middle Aged
(23)
Botulinum Toxins, Type A - Therapeutic Use
(20)
Adult
(19)
Antibodies
(15)
Botulinum Toxin
(15)
Torticollis - Drug Therapy
(14)
Botulinum Toxins, Type A - Immunology
(13)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy

Botulinum Neurotoxin Is Shielded by NTNHA in an Interlocked Complex

The role of human serum albumin and neurotoxin associated proteins in the formulation of BoNT/A products

Botulinum Neurotoxins: Qualitative and Quantitative Analysis Using the Mouse Phrenic Nerve Hemidiaphragm Assay (MPN)

The HCC‐domain of botulinum neurotoxins A and B exhibits a singular ganglioside binding site displaying serotype specific carbohydrate interaction

Heinrich Heesch: Kristallgeometrie, Parkettierungen, Vierfarbenforschung

Clinical relevance of neutralizing antibodies in botulinum toxin long-term treated still-responding patients with cervical dystonia

Synaptotagmins I and II Act as Nerve Cell Receptors for Botulinum Neurotoxin G

Botulinum toxin type D blocks autonomic cholinergic synapses in humans: discussion of a potential therapeutic use

Identification of the protein receptor binding site of botulinum neurotoxins B and G proves the double-receptor concept

The biological activity of botulinum neurotoxin type C is dependent upon novel types of ganglioside binding sites

Botulinum neurotoxin serotype D attacks neurons via two carbohydrate-binding sites in a ganglioside-dependent manner

Two Carbohydrate Binding Sites in the HCC-domain of Tetanus Neurotoxin are Required for Toxicity

SNARE tagging allows stepwise assembly of a multimodular medicinal toxin

Botulinum neurotoxin type A in urology: Antibodies as a cause of therapy failure

Long-term stability of reconstituted incobotulinumtoxinA: how can we reduce costs of botulinum toxin therapy?

Reconstituting botulinum toxin drugs: shaking, stirring or what?

Reconstituting botulinum toxin drugs: Shaking, stirring or what?

Comparing incobotulinumtoxina (Xeomin) and onabotulinumtoxina (Botox): Identical potency labeling in the hemidiaphragm assay

Complexing proteins: Are they necessary for mechanical stability of botulinum toxin drugs?

The immunology of botulinum toxin therapy: A brief summary

Botulinum toxin: application, safety, and limitations

Comparing incobotulinumtoxinA (Xeomin®) and onabotulinumtoxinA (Botox®): identical potency labelling in the hemidiaphragm assay

Botulinum toxin A and the cutaneous nociception in humans: A prospective, double-blind, placebo-controlled, randomized study

Botulinum toxin antibody type A titres after cessation of botulinum toxin therapy

Suchergebnisse filtern